Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

Stopped early

Conditions studied: Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease

In brief

The objective of this study is as follows: * Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS) * Perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with FSGS * Determine if patients with mutations in specific proteins are more likely to have cardiovascular abnormalities * Initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality

Key facts

Study ID

NCT00883636

Run by

Northwell Health

People needed

4

Starts

2008-10-01

Expected to finish

2011-10-01

Last updated by the study team

2013-06-19

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 6 months - 21 years
• SRNS, defined as failure to achieve remission in proteinuria after 4-6 weeks of daily steroid therapy in accord with ISKDC guidelines
• GFR > 30 ml/min/1.73 m\^2
• Renal disease diagnosed based on kidney biopsy

You may not qualify if…

• Secondary FSGS
• Prior renal transplantation
• Congenital extra-renal abnormalities
• Significant structural cardiac abnormalities
• pulmonary, hematologic, malignancy, or immune-related disease
• inability to maintain adequate follow-up

Where it is running

• Schneider Children's Hospital — New Hyde Park, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.